SCHEMBL5135166

SCHEMBL5135166

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(F)c(F)c1)CC1CCCCC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.45
P2RX7 Q99572 5/20 0.37
TSHR P16473 4/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
CYP3A4 P08684 3/20 0.36
HSD17B10 Q99714 3/20 0.36
HPGD P15428 2/20 0.36
CRHR1 P34998 2/20 0.34
HDAC1 Q13547 1/20 0.34
ALOX15 P16050 1/20 0.34
CCR4 P51679 1/20 0.33
BCHE P06276 3/20 0.33
ADORA3 P0DMS8 1/20 0.33
ADORA2A P29274 1/20 0.33
ADORA2B P29275 1/20 0.33
ADORA1 P30542 1/20 0.33
ACHE P22303 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL647516 0.93 C5AR1 (0.43) C5AR1P2RX7TSHRKDM4EALDH1A1
SCHEMBL651431 0.93 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL649094 0.93 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL650928 0.93 C5AR1 (0.43) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135213 0.92 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL651006 0.92 C5AR1 (0.42) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5135694 0.91 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4
SCHEMBL5137114 0.91 C5AR1 (0.43) C5AR1P2RX7TSHRKDM4EALDH1A1
SCHEMBL650474 0.90 C5AR1 (0.42) C5AR1P2RX7TSHRKDM4EALDH1A1
SCHEMBL5135713 0.89 C5AR1 (0.44) C5AR1TSHRKDM4EALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed